Topline data from this study is expected in December 2024, with the full 12-month safety study concluding in Q1 2025.
2 Likes
Wikipedia says this about the mechanism of action of Brilaroxazine:
" Brilaroxazine acts as a potent partial agonist of D2, D3, D4 and 5-HT1A receptors, and as an antagonist of 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6 and 5-HT7 receptors.[9][11] Brilaroxazine exhibits high affinity for D2S, D2L, D3, D4.4, 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors, and moderate affinity for D1, D5, 5-HT2C, 5-HT3, 5-HT6, H1 and α4β2 nicotinic receptors, the serotonin transporter, and the α1B adrenergic receptor.[9][11] It lacks significant affinity for 5-HT1B, α2 adrenergic, and muscarinic acetylcholine receptors, as well as for the norepinephrine and dopamine transporters."
Let’s say it’s similar to agonists like vraylar or rexulti, or caplyta?
2 Likes
Its supposed to be potent with good side effect profile. The company will have to raise funds or find a partner to continue. If there is further progress, it looks like late 2026 or 2027.Resourceful Japanese patient has this article:
https://matsblog.net/en/entry/antipsychotics-brilaroxazine-en
2 Likes